NCT00996840 - SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2009

Primary Completion Date

February 9, 2013

Study Completion Date

February 9, 2013

Conditions

Lung Injury, Acute

Interventions

DRUG

SB-681323 Intravenous 3mg

3 mg SB-681323 Intravenous administration infused over 4 hours

DRUG

SB-681323 Intravenous 7.5 mg

7.5 mg SB-681323 Intravenous administration infused over 24 hours

DRUG

SB-681323 Intravenous 7.5mg

7.5 mg SB-681323 Intravenous administration infused over 4 hours

DRUG

SB-681323 Intravenous 10mg

10 mg SB-681323 Intravenous administration infused over 24 hours

OTHER

Placebo

Placebo to match intervention

Trial Locations (6)

GSK Investigational Site, Pittsburgh

GSK Investigational Site, Philadelphia

GSK Investigational Site, Winston-Salem

GSK Investigational Site, Durham

GSK Investigational Site, Lexington

GSK Investigational Site, Nashville